Adenomyoepithelioma of the Breast: Diagnosis, Treatment and Surveillance at Tertiary Cancer Center
Deepak Singh Mouni *1, Sulochana Shrestha 2, Ankita Adhikari 3
1,2,3. Breast Onco Surgery Unit, Sugical Oncology Depatment, B.P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal.
Corresponding Author: Deepak Singh Mouni, Breast Onco Surgery Unit, Sugical Oncology Depatment, B.P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal.
Copy Right: © 2023 Deepak Singh Mouni, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received Date: May 08, 2023
Published Date: June 01, 2023
Adenomyoepithelioma is a rare, benign breast neoplasm characterized by the proliferation of both epithelial and myoepithelial cells within the breast lobules and ducts. Although it is most commonly seen in salivary glands and skin, Hamper reported the first case in the breast in the 1970 (1). While this benign tumor is predominantly found in older females, rare cases have been identified in young women as well. Adenomyoepithelioma is notorious for local recurrence, and malignant metastasis has been reported (2).
Adenomayoepithelioma is very rare case in 10 years, out of 19000 case evaluation & diagnosis we have encountered only 2 cases, 1 was referred case & 1 diagnosed at B.P. Koirala Memorial Cancer Hospital Breast Oncosurgery Department.
Adenomyoepitheliomas typically presents as a single, palpable, well-circumscribed, firm mass, with dimensions of up to 8 cm. Microscopic satellite lesions may be present in the periphery of the tumor at times, but it is mostly located in the central portion. Rarely, adenomyoepitheliomas may also present in phyllodes tumor or fibroadenoma. Pain and nipple discharge are rare symptoms associated with adenomyoepitheliomas. (15)
Radiology imaging is not specific and cannot distinguish between benign and malignant lesions (2). Ultrasonography (USG) shows that adenomyoepitheliomas are typically solid or have a combined solid and cystic appearance. On mammography, they present as a lobulated dense mass with a partially indistinct margin, with or without calcifications. Malignant adenomyoepitheliomas show irregular shapes with spiculated margins on mammography. (14)
FNAC and core needle biopsy are also rarely diagnostic due to the heterogeneity of the tumor, with many cases falsely diagnosed as fibroadenoma in the literature. However, the presence of tightly aggregated glands arranged in compact nodules and prominent clear cell or spindle cell myoepithelium can be clues to the diagnosis. (4) (8) (13)
IHC is an important tool in the diagnosis of adenomyoepithelioma. The panel of markers, including p63, S-100, and HMWCK.P63 is a transcription factor that is expressed in the nuclei of myoepithelial cells and is a very sensitive and specific marker for identifying these cells. In adenomyoepithelioma, P63 staining is typically positive and shows a consistent rim of staining around the epithelial cells, which can help to distinguish it from other breast tumors. Ki-67 proliferation index is also useful in predicting the recurrence rate of the tumor. ER, PR, and HER-2 are usually negative in malignant adenomyoepithelioma. (6) (7) (9) (12)
No specific guidelines have been established for the treatment of adenomyoepithelioma. However, wide local excision with negative margins is recommended due to the local recurrence nature of the tumor. Some cases of malignant adenomyoepithelioma have also been reported in the literature, where mastectomy and sentinel lymph node biopsy are recommended. (10) (11)
Benign adenomyoepitheliomas generally have a good prognosis but require close monitoring and follow- up. In cases of local recurrence, radiotherapy has been used with positive results. However, malignant adenomyoepithelioma has a poor prognosis due to its low-grade invasiveness, high recurrence rate, and resistance to chemotherapy. Malignant tumors are more likely to metastasize via hematogenous spread to distant organs such as the brain, liver, and lungs rather than through the lymphatic system. (10) (11)
Patient diagnosed with AMEs should be followed every 3 month for first 3 Year, then every 6 months for 2 years. After Year of surveillance and without any sigh of recurrence pt should have regular follow up early.
Adenomyoepitheliomas (AMEs) are uncommon benign breast tumors that should be considered in the differential diagnosis of solid breast lumps. While imaging features are not specific, suspicion of benign or malignant nature can be raised through radiologic examination. FNAB is often not diagnostic. Currently, there are no established guidelines for treating either benign or malignant AME. Surgical excision with negative margins is recommended for both types of AME due to the high recurrence rate for benign tumors and the aggressiveness of malignant ones. Close monitoring and follow-up are necessary for benign cases, while malignant cases have a poor prognosis and are characterized by low grade, invasiveness, and high recurrence rate. Chemotherapy is not effective for treating malignant AME, and metastasis occurs through hematogenous spread to organs such as the brain, liver, and lungs.
Keywords: Adenomyoepithelioma; Asymptomatic; Benign mass; Case report; Surgical excision; Treatment; surveillance.